Aurozyme: A Revolutionary Nanozyme in Colitis, Switching Peroxidase‐Like to Catalase‐Like Activity
Small · 2023
DOI: 10.1002/smll.202302331 ↗Kurz gefasst
Fachartikel in der Zeitschrift Small, 2023. Verfasst von Hyung Shik Kim und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Bioengineering, College of Engineering, and BK FOUR Biopharmaceutical Innovation Leader for Education and Research Group, Hanyang Unive…. Hauptthemen laut MEDLINE: Metal Nanoparticles, Colitis. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 54 Literaturangaben. Gefördert von: National Research Foundation of Korea.
Abstract (Originalsprache)
A therapeutic strategy that could address colitis of multiple etiologies while restoring the dysbiosis of gut microbiota is attractive. Here, Aurozyme, a novel nanomedicine comprised of gold nanoparticles (AuNPs) and glycyrrhizin (GL) with a glycol chitosan coating layer, as a promising approach for colitis, is demonstrated. The unique feature of Aurozyme is the conversion of harmful peroxidase‐like activity of AuNPs to beneficial catalase‐like activity due to the amine‐rich environment provided by the glycol chitosan. This conversion process enables Aurozyme to oxidize the hydroxyl radicals derived from AuNP, producing water and oxygen molecules. In fact, Aurozyme effectively scavenges reactive oxygen/reactive nitrogen species (ROS/RNS) and damage‐associated molecular patterns (DAMPs), which can attenuate the M1 polarization of macrophage. It exhibits prolonged adhesion to the lesion site, promoting sustained anti‐inflammatory effects and restoring intestinal function in colitis‐challenged mice. Additionally, it increases the abundance and diversity of beneficial probiotics, which are essential for maintaining microbial homeostasis in the gut. The work highlights the transformative potential of nanozymes for the comprehensive treatment of inflammatory disease and represents an innovative switching technology of enzyme‐like activity by Aurozyme.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Bioengineering, College of Engineering, and BK FOUR Biopharmaceutical Innovation Leader for Education and Research Group, Hanyang University, Seoul, 04763, Republic of Korea.
- Institute of Nano Science and Technology (INST), Hanyang University, Seoul, 04763, Republic of Korea.
- Institute for Bioengineering and Biopharmaceutical Research (IBBR), Hanyang University, Seoul, 04763, Republic of Korea.
- Elixir Pharmatech Inc., Seoul, 07463, Republic of Korea.
ORCID-Profile: Hyung Shik Kim, Dong Yun Lee
Förderung
- National Research Foundation of Korea
Zitieren
APA
Kim, H. S., Lee, S., & Lee, D. Y. (2023). Aurozyme: A Revolutionary Nanozyme in Colitis, Switching Peroxidase‐Like to Catalase‐Like Activity. Small. https://doi.org/10.1002/smll.202302331
Vancouver
Kim HS, Lee S, Lee DY. Aurozyme: A Revolutionary Nanozyme in Colitis, Switching Peroxidase‐Like to Catalase‐Like Activity. Small. 2023. doi:10.1002/smll.202302331
BibTeX
@article{Kim2023,
author = {Kim, Hyung Shik and Lee, Sieun and Lee, Dong Yun},
title = {Aurozyme: A Revolutionary Nanozyme in Colitis, Switching Peroxidase‐Like to Catalase‐Like Activity},
journal = {Small},
year = {2023},
doi = {10.1002/smll.202302331}
}
EUVIMED